When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
FOLD - Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering
Amicus Therapeutics Inc.
Amicus Therapeutics (FOLD) is a commercial stage biopharma that is seeing huge sales growth of its one marketed product, Galafold, which treats Fabry disease. Sales of Galafold are expected to easily exceed $1 billion as are sales of Amicus' late-stage therapy for Pompe disease, AT-GAA. Despite this, Amicus currently has a market cap of just over $3 billion. In this article, I will provide an overview of the company and discuss why I think Amicus is a strong value proposition for long-term investors.